Who are IM olanzapine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quetiapine (drug), Lithium carbonate + perospirone hydrochloride, risperidone (Risperdal), Fluoxetine+Olanzapine, Quetiapine or Risperidone + Aripiprazole, sodium valproate with Clozapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/im-olanzapine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IM olanzapine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IM olanzapine (IM olanzapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

IM olanzapine (IM olanzapine) — National Taiwan University Hospital. IM olanzapine is an intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IM olanzapine TARGET	IM olanzapine	National Taiwan University Hospital	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine (drug)	Quetiapine (drug)	Medical University of Vienna	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Lithium carbonate + perospirone hydrochloride	Lithium carbonate + perospirone hydrochloride	Shanghai Mental Health Center	marketed	Mood stabilizer + atypical antipsychotic combination	Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
risperidone (Risperdal)	risperidone (Risperdal)	University of South Florida	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Fluoxetine+Olanzapine	Fluoxetine+Olanzapine	University Health Network, Toronto	marketed	SSRI + atypical antipsychotic combination	Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine or Risperidone + Aripiprazole	Quetiapine or Risperidone + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

Shanghai Mental Health Center · 10 drugs in this class
AstraZeneca · 6 drugs in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
Eli Lilly and Company · 4 drugs in this class
Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
Medical University of Vienna · 2 drugs in this class
Organon and Co · 2 drugs in this class
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IM olanzapine — Competitive Intelligence Brief. https://druglandscape.com/ci/im-olanzapine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing